Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders [16]

Leukemia

Volumn 20, Issue 1, 2006, Pages 168-171

  McClure, R ^a   Mai, M ^a   Lasho, T ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; JANUS KINASE 2; PHENYLALANINE; VALINE;

ALLELE; B CELL LEUKEMIA; BLOOD SAMPLING; BONE MARROW BIOPSY; BONE MARROW CELL; CAPILLARY ELECTROPHORESIS; CHRONIC DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FLUORESCENCE ANALYSIS; FOLLICULAR LYMPHOMA; GENE AMPLIFICATION; HUMAN; LETTER; MANTLE CELL LYMPHOMA; MAST CELL; MYCOSIS FUNGOIDES; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POINT MUTATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEZARY SYNDROME; T CELL LEUKEMIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VALIDATION PROCESS; WILD TYPE;

EID: 33644969827     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404007     Document Type: Letter

References (8)

1. Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
2. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
3. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162-2168.
4. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
5. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL et al. Brief Report: The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and the myelodysplastic syndrome. Blood 2005; 106: 1207-1209.
6. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia. Blood 2005, Prepublished online July 21.
7. Levine RL, Loriaux M, Huntly BJP, Loh ML, Beran M, Stoffregen E et al. The JAK2V617F activating mutation in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005, Prepublished online August 4.
8. James C, Ugo V, LeCouedic J-P, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 1144-1148.